Indications
| Mesh Heading | Maximum Phase | Reference |
|---|---|---|
| Glioblastoma; Gliosarcoma | Phase 2 | ClinicalTrials |
| Lung Neoplasms; Small Cell Lung Carcinoma | Phase 1 | ClinicalTrials |
| Central Nervous System Neoplasms; Glioblastoma; Nervous System Neoplasms | Phase 1 | ClinicalTrials |
| Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Lymphomatoid Granulomatosis; Plasmablastic Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Waldenstrom Macroglobulinemia | Phase 1 | ClinicalTrials |
| Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid | Phase 1/Phase 2 | ClinicalTrials |
| Adrenocortical Carcinoma; Carcinoma | Phase 2 | ClinicalTrials |
| Lung Neoplasms; Small Cell Lung Carcinoma | Phase 2 | ClinicalTrials |
| Multiple Myeloma; Neoplasms, Plasma Cell | Phase 1/Phase 2 | ClinicalTrials |
CONTENTS